Cargando…
Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway
Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective hypoglycemic drug; however, the effects of empagliflozin on hepatic g...
Autores principales: | Yu, Xiaochen, Meng, Ziyu, Fang, Ting, Liu, Xiaohuan, Cheng, Ying, Xu, Linxin, Liu, Xiangyang, Li, Xiaoyu, Xue, Mei, Li, Ting, Sun, Bei, Chen, Liming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921641/ https://www.ncbi.nlm.nih.gov/pubmed/35299662 http://dx.doi.org/10.3389/fphys.2022.817542 |
Ejemplares similares
-
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro
por: Li, Ting, et al.
Publicado: (2021) -
Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes
por: Xu, Linxin, et al.
Publicado: (2021) -
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019) -
Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice
por: Lu, Yun-hong, et al.
Publicado: (2020) -
Disrupting AMPK-Glycogen Binding in Mice Increases Carbohydrate Utilization and Reduces Exercise Capacity
por: Janzen, Natalie R., et al.
Publicado: (2022)